We searched databases for studies that evaluated the expression of Notch receptors and/or ligands in human HCC tissue.
HCC is the fifth most common malignancy and second leading cause of cancer-related death worldwide; its 5-year survival rate is 15–17%3.
Therefore, early screening, early diagnosis, and initial treatment are appropriate ways to determine the prognosis of patients with liver cancer, which is important.
Numerous related factors and molecular pathways are involved in the pathogenesis and progression of HCC.
The Notch signaling pathway is composed of Notch receptors (Notch 1–4), Notch ligands (Delta 1,3,4; Jagged 1–2) and intracellular effector molecules and is a highly conserved intercellular signal transduction pathway.
The Notch signaling pathway is pleiotropic, and activation of this pathway not only plays an important role in the development and differentiation of normal cells but also plays an important role in the evolution of the disease, especially in corresponding tumor formation8,9.
In recent years, studies on the role of the Notch signaling pathway in carcinogenesis and suppression of primary HCC have made progress.
Some studies suggest that expression of Notch receptors or ligands in HCC can inhibit the proliferation of HCC cells, while the opposite view is that high expression of some Notch receptors or ligands, such as Notch 1 or Jagged1, can promote the differentiation of liver tumor and tumor vascular proliferation.
To provide new guidelines for early detection or early diagnosis, establish an individualized treatment regimen and evaluate of prognosis of HCC, this systematic review and meta-analysis observed the expression levels of Notch l–4 and Jagged l in HCC tissue, pericarcinomatous tissue and normal control tissue.
Full size image The association between the Notch receptor/ligand in HCC and non-HCC tissues.
A receiver-operating characteristic (ROC) analysis was used to classify patients as follows: NLR-PNI 0 group (NLR ≤ 2.2 and PNI > 46), NLR-PNI 1 group (NLR > 2.2 or PNI ≤ 46) and NLR-PNI 2 group (NLR > 2.2 and PNI ≤ 46).
Regarding 1-, 3-, and 5-year survival, the NLR-PNI score had superior discriminative abilities (i.e., higher area under the ROC curve), compared with either the NLR or PNI alone, and patients in the NLR-PNI 0, 1, and 2 groups had median survival times of 33 (95% confidence interval: 22.8–43.2), 14 (10.9–17.1), and 6 (9.9–14.1) months, respectively.
However, studies have also shown that not all patients with unresectable HCC benefit from TACE.
A new inflammation-based score system, the NLR-PNI score, was then generated by combining the NLR score with the PNI score.
Full size image This study included 793 patients with unresectable HCC who had undergone TACE during the study period and for whom complete data were available.
Overall, 54.2% of the patients received >1 TACE treatment (range: 1–9).
(A) Overall survive; (B) NLR; (C) PNI; (D) NLR-PNI score.
As the prognostic values of the NLR and PNI are stable in patients with early-stage HCC, we evaluated whether a combination of these scores could optimize the selection of patients who would benefit from TACE among a patient subgroup with varying tumour burdens and variable predicted survival outcomes.
Our results indicated that the combined NLR-PNI score could better reflect the systemic inflammatory response for patients with HCC after TACE, compared with either score alone.
After dividing our patients into three groups according to NLR-PNI scores, we found that those with high combined scores had progressively worse outcomes relative to those with lower scores, and these differences were largely significant.
The role of the gene EZH2 in colorectal cancer survival is uncertainly, the aim of this study is clear this relationship. A meta-analysis was performed with elegible studies which quantitatively evaluated the relationship between EZH2 overexpression and survival of patients with colorectal cancer. Combined hazard ratios suggested that EZH2 overexpression was associated with better prognosis of overall survival (OS) HR(hazard ratio) = 0.61 95% CI (0.38–0.84) We performed bias analysis according Egger and Begg,s test and we did not find publication bias. EZH2 overexpression indicates a better prognosis for colorectal cancer.
One of the mechanisms that regulate histone epigenetic modification is mediated by the polycomb repressive complexes (PcG).
The present work undertakes a systematic review of studies that include the analysis of the expression of EZH2, and attempts to evaluate its influence over prognosis in CRC, through an analysis of the overall survival rates. Additionally, the methodological quality of the selected studies was assessed.
The initial search was undertaken with no limitations as to language, but full paper reading and later assessment were only completed in works published in English.
An analysis of publication bias was carried out with the methods proposed by Egger et al.33 and Begg & Mazumdar34.
The purpose of this study was to conduct a comprehensive study of the clinical correlation between the alpha-fetoprotein (AFP) level at diagnosis and pathological grades, progression, and survival of patients with hepatocellular carcinoma (HCC). A total of 78,743 patients in Surveillance, Epidemiology, and End Results Program (SEER)-registered HCC was analyzed. Multivariable Cox regression analyses identified AFP level as an independent predictor of survival risk of patients with HCC who did not undergo surgery (hazard ratio [HR], 1.660; 95% CI, 1.534–1.797; P < 0.001), and those who underwent surgery (HR, 1.534; 95% CI, 1.348–1.745; P < 0.001). The AFP level at diagnosis was an independent risk predictor associated with pathological grade, progression, and survival.
More than 250,000 new cases of HCC occur annually, and approximately 500,000–600,000 patients die each year2,3. Approximately 50% of HCCs secrete AFP7,8, and a plasma AFP concentration >400 ng/ml is generally considered a reliable for supporting the diagnosis of HCC. Because the accuracy of the AFP concentration was challenged as well as a growing debate about its ongoing use for HCC surveillance programs, AFP was removed from updated international guidelines for HCC surveillance. However, many reports suggest a rationale for the continued use of AFP9,10,11.
To identify the clinical significance of AFP levels, in the present study we analyzed the comprehensive clinical relationship between the AFP levels and pathological grades, progression, and survival of patients with HCC using the data for patients with HCC that were deposited in the cancer registry of the Surveillance, Epidemiology, and End Results (SEER) Program from 1988 through 2013.
We assessed the relationship between the heterogeneity of HCC on preoperative non-contrast-enhanced CT and patient prognosis. The heterogeneity of CT images from 122 patients was assessed and texture feature parameters such as mean, standard deviation (SD), entropy, mean of the positive pixels (MPP), skewness, and kurtosis were obtained using filtration. CT texture features of non-contrast-enhanced CT images showed a relationship with HCC prognosis. We assessed the relationship between the heterogeneity of HCC on preoperative non-contrast-enhanced CT and patient prognosis. The heterogeneity of CT images from 122 patients was assessed and texture feature parameters such as mean, standard deviation (SD), entropy, mean of the positive pixels (MPP), skewness, and kurtosis were obtained using filtration. CT texture features of non-contrast-enhanced CT images showed a relationship with HCC prognosis.
In this study, we showed the significance of non-contrast-enhanced CT images in the assessment of HCC prognosis. In this study, we showed the significance of non-contrast-enhanced CT images in the assessment of HCC prognosis.
performed the study. performed the study.